Mitralign has announced the enrollment of the first patient in a study of the company’s Trialign system for the treatment of tricuspid regurgitation in certain patients.
The study will assess the early safety and feasibility of the device, according to the company.
Mitralign CEO Rick Geoffrion says an estimated 1.6 million patients in the U.S. suffer from tricuspid regurgitation, but there has been limited progress in developing tricuspid-specific therapies.
Mitralign is a valve repair company headquartered in Tewksbury, Mass. — Michael Cipriano